Fresh analysis reveals that individuals who discontinue new slimming jabs like Wegovy and Mounjaro can put back on shed pounds far faster than those who halt conventional diet and exercise programs.
Research printed in a prominent medical journal shows that while obese people often shed a large proportion of their total mass while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month once they quit.
"People buying such treatments should be informed of the risk of rapid weight regain when the therapy concludes," cautioned expert Dr. Susan Jebb.
This pace of recovery implies a reversion to original mass in about one and a half years.
Weighing Treatments
The analysis, which reviewed 37 of studies involving thousands of patients, compared the outcomes of the injectable medications with older methods.
Researchers emphasize that individuals who shed pounds through lifestyle changes alone generally see a less rapid creep back—approximately 100 grams monthly—after stopping.
Explaining the Quick Rebound
Nutrition scientists propose the mechanism of the jabs explains the amplified rebound.
GLP-1 drugs mimic a body's own chemical called GLP-1, which helps regulate hunger.
"Artificially providing the hormone levels far above than the body's typical production might result in the body to produce less of its own natural GLP-1, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication means appetite is unsuppressed, making overeating a significant risk."
A Chronic Issue?
The NHS suggest the injections for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Many experts argue that, given the significant potential of relapse, the treatment is often ongoing.
This opinion is echoed by pharmaceutical companies, who note that the findings "highlight the persistent character of obesity," similar to managing conditions like high blood pressure.
User Accounts
Individuals who have come off the jabs explain a powerful return of hunger.
"It felt as if a switch flipping and I was suddenly ravenous," described an individual.
The struggle is worsened if users have not adopted sustainable dietary or behavioural changes during therapy.
Significant Use
Survey data show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Use is more common among females compared to males.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are powerful agents for shedding pounds, they are not a permanent solution and maintained weight loss hinges on integrated lifestyle management.
